Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Merck
Cipla
Harvard Business School
Johnson and Johnson
Cerilliant
Farmers Insurance
QuintilesIMS
Mallinckrodt

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ROSIGLITAZONE MALEATE

« Back to Dashboard

Clinical Trials for Rosiglitazone Maleate

Trial ID Title Status Sponsor Phase Summary
NCT00131664 Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) Completed GlaxoSmithKline Phase 3 The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes Association guidelines glucose control, based on the A1C measurement, needs to be achieved within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The guidelines on the use of antihyperglycemic agents identify the potential benefits of sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral antihyperglycemic monotherapy who then start on combination therapy may not achieve the required target glycemic control. Indeed early initiation of combination therapies may be necessary to achieve and maintain glycemic targets because of the progressive deterioration of pancreatic β cell function and glycemic control.
NCT00131664 Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) Completed Canadian Heart Research Centre Phase 3 The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes Association guidelines glucose control, based on the A1C measurement, needs to be achieved within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The guidelines on the use of antihyperglycemic agents identify the potential benefits of sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral antihyperglycemic monotherapy who then start on combination therapy may not achieve the required target glycemic control. Indeed early initiation of combination therapies may be necessary to achieve and maintain glycemic targets because of the progressive deterioration of pancreatic β cell function and glycemic control.
NCT00143624 Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels Completed University of British Columbia N/A This trial will study the effect of rosiglitazone on the progression of atherosclerosis (hardening of blood vessels) through improvements of the sugar and fat metabolism (body buildup, breakdown and excretion of sugar and fat). Participants will be randomly assigned to one of two groups: the first group will receive 8 mg of the study drug and the second group will be given a placebo, though neither group will know which formulation they are receiving. The study will follow both groups for one year, during which it will measure changes in blood vessel composition and activity, sugar metabolism, concentration of blood fat, and body fat distribution. This single-site study aims to enroll 50 participants.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Rosiglitazone Maleate

Condition Name

Condition Name for Rosiglitazone Maleate
Intervention Trials
Diabetes Mellitus, Type 2 5
Diabetes Mellitus 2
Oral Leukoplakia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rosiglitazone Maleate
Intervention Trials
Diabetes Mellitus 10
Diabetes Mellitus, Type 2 9
Leukoplakia, Oral 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rosiglitazone Maleate

Trials by Country

Trials by Country for Rosiglitazone Maleate
Location Trials
United States 87
Germany 10
Mexico 10
Canada 6
United Kingdom 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rosiglitazone Maleate
Location Trials
California 5
New York 4
Tennessee 3
Minnesota 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rosiglitazone Maleate

Clinical Trial Phase

Clinical Trial Phase for Rosiglitazone Maleate
Clinical Trial Phase Trials
Phase 3 8
Phase 2 2
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rosiglitazone Maleate
Clinical Trial Phase Trials
Completed 13
Withdrawn 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rosiglitazone Maleate

Sponsor Name

Sponsor Name for Rosiglitazone Maleate
Sponsor Trials
GlaxoSmithKline 8
National Cancer Institute (NCI) 2
Takeda 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rosiglitazone Maleate
Sponsor Trials
Industry 14
Other 4
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Deloitte
Daiichi Sankyo
Chubb
Fish and Richardson
Express Scripts
US Army
Farmers Insurance
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.